Verastem, Inc. (VSTM)
VSTMNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$8.75
+0.3900 (+4.67%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $1.10bn
- P/E
- –
- EPS, last 4 quarters
- $-2.05
- Dividend yield
- –
- Day range
- –
- 52-week range
- $3.43 to $10.82
- Average volume
- 3.77m
- Previous close
- $8.36
Analysts
7 coveringBuy7 buy, 0 hold, 0 sell
Targets a year out average $18.50, +111.4% from here
Earnings
next estimate $-0.3700Next report
Dec 2025
-2.0%
Mar 2026
0.0%
Jun 2026
+23.9%
Sep 2026
-68.2%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $11.24m | $17.54m | $18.67m | $40.08m |
| Gross profit | $9.28m | $14.64m | $15.62m | $36.04m |
| Operating income | -$40.72m | -$41.48m | -$44.90m | -$32.71m |
| Net income | -$98.52m | -$32.92m | -$36.59m | -$34.67m |
Last four quarters: revenue $87.53m, margin -231.6%, free cash flow –
News
8 latest- What Verastem (VSTM) Said on Its Q3 Earnings CallMarketBeat · 3 days ago
- Verastem (VSTM) Q3 2026 Earnings Call TranscriptThe Motley Fool · 3 days ago
- Verastem (VSTM) Reports Q3 Loss, Misses Revenue EstimatesZacks · 4 days ago
- Clene Inc. (CLNN) Tops Q3 Earnings EstimatesZacks · 6 days ago
- Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass EstimatesZacks · Oct 27, 2026
- Verastem Consensus Price Target Increased by 17.42% to $17.57Fintel · Oct 23, 2026
- Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase IIIMarketBeat · Oct 14, 2026
- Verastem Surges Ahead With VS-7375 Cancer Data, $250M Offering And New CEO Appointment RTTNews · Oct 14, 2026
The company
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI FAKZYNJA CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- verastem.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.